HBV Treatment
Entecavir Alone Works as Well as Combo for First-time Hepatitis B Treatment
- Details
- Category: Approved HBV Drugs
- Published on Wednesday, 10 October 2012 00:00
- Written by Liz Highleyman
Treating chronic hepatitis B with entecavir (Baraclude) alone worked as well as dual therapy using entecavir plus tenofovir (Viread) for patients starting treatment for the first time, according to a study described in the September 2012 issue of Gastroenterology. 
Adefovir-resistant Hepatitis B Virus Can Remain Susceptible to Tenofovir
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 02 October 2012 00:00
- Written by Liz Highleyman
Tenofovir (Viread) continues to be effective for treating chronic hepatitis B patients who have developed resistance to the related drug adefovir (Hepsera), according to a report in the August 14, 2012, online edition of Antiviral Therapy.
Tenofovir Is Safe and Effective for Treating Hepatitis B in Adolescents
- Details
- Category: Approved HBV Drugs
- Published on Wednesday, 26 September 2012 00:00
- Written by Liz Highleyman
Teenagers with chronic hepatitis B virus (HBV) infection responded well to 2 years of treatment with tenofovir (Viread) in the first study of the drug in this population, researchers reported in the August 27, 2012, advance online edition of Hepatology.
Heavy Alcohol Use Impairs Biochemical Response to Entecavir for Chronic Hepatitis B
- Details
- Category: Approved HBV Drugs
- Published on Friday, 28 September 2012 00:00
- Written by Liz Highleyman
While obese chronic hepatitis B patients and heavy drinkers did not have impaired virological response to entecavir (Baraclude), alcohol use did reduce the likelihood of alanine aminotransferase (ALT) normalization, according to study findings reported in the June 2012 issue of Clinical and Molecular Hepatology. 
Tenofovir Hepatitis B Label Update Adds Info on Adolescents, Long-term Data for Adults
- Details
- Category: HBV Treatment
- Published on Thursday, 30 August 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) this week announced that product label information for tenofovir (Viread) has been revised to include further information about treatment of chronic hepatitis B in teenagers and 240-week data for adult patients. 
Web Design and Development by